Abstract
Background: One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome.
Objective: To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19.
Study design: In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously.
Results: 171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups.
Conclusion: In hospitalized patients with severe COVID-19, anti-IL-17 therapy might mitigate the inflammatory response and improve oxygenation, but do not affect the need for mechanical ventilation and mortality.
Keywords: COVID-19; Cytokine storm; IL-17; Netakimab; Therapeutics.
【저자키워드】 COVID-19, Cytokine storm, Therapeutics, netakimab, IL-17, 【초록키워드】 Efficacy, therapy, Mortality, intensive care, severe COVID-19, mechanical ventilation, multi-organ dysfunction, Therapeutics, 28-day mortality, CRP, ICU, Clinical outcome, Patient, Efficacy and safety, inhibitor, Other, body temperature, case-control study, retrospective, Inflammatory response, dose, Oxygenation, Standard of care, NEWS2, control group, experimental group, syndrome, transfer, lung tissue, pathophysiological mechanism, SpO2/FiO2, mitigate, IMPROVE, Course, enrolled, not differ, evaluate, significantly, involved, evaluated, treated, hospitalized patient, suggested, not affect, groups, subcutaneously, 【제목키워드】 monoclonal antibody, pilot study, hospitalized patient,